title: Proliferative retinopathy in Duchenne muscular dystrophy and its response to bevacizumab.
authors.forename: Xavier J
authors.initials: XJ
authors.lastname: Fagan
authors.forename: Jaime
authors.initials: J
authors.lastname: Levy
authors.forename: Salmaan
authors.initials: S
authors.lastname: Al-Qureshi
authors.forename: C Alex
authors.initials: CA
authors.lastname: Harper
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000150:complications*; D015861:Retinal Neovascularization / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab